Prana shares up premarket on clinical trial update

|About: Prana Biotechnology Ltd (PRAN)|By:, SA News Editor

Shares of Prana Biotechnology (NASDAQ:PRAN) are up 13% premarket on robust volume in response to the company's disclosure of results from a Phase 2 clinical trial of PBT2 as a treatment for patients with Alzheimer's disease.

In a sub-analysis of results originally disclosed on March 31, 2014 Professor Colin Masters found that the subgroup of PBT2-treated patients with a baseline SUVR above the Phase 2 trial mean of 2.5 showed a significant decrease in amyloid burden compared to placebo and compared to the test group with an SUVR value below 2.5. His findings will impact the design of future clinical trials to assess the safety and efficacy of PBT2 in this subgroup of AD sufferers.